Loading...
By Kelly Young
Edited by André Sofair, MD, MPH, and William E. Chavey, MD, MS
Azathioprine use is associated with increased risk for acute pancreatitis among youth with inflammatory bowel disease, falling in line with previous studies in adults, according to a study in the Lancet Child & Adolescent Health.
Using national health registries in Denmark and Switzerland, researchers identified 8700 pediatric patients with inflammatory bowel disease. The year following a new prescription for azathioprine was compared with years in which no thiopurines were prescribed.
In the first 90 days after a new azathioprine prescription, the rate of acute pancreatitis events was significantly higher than in the no-use group (1.2% vs. 0.2%). The median time to acute pancreatitis was 23 days in the azathioprine group.
The authors conclude: "The observed high risk shortly after treatment initiation supports regular and rigorous monitoring during this period."
Comment
LINK(S):
The Lancet Child & Adolescent Health article (Free abstract)
Background: NEJM Journal Watch Gastroenterology coverage of 6-MP use when azathioprine is not well tolerated (Your NEJM Journal Watch registration required)